Gelonghui, Feb. 3 丨 Kangji Healthcare (9997.HK) bucked the trend and rose more than 9%. The intraday high of HK$10.54 hit a 17-month high, with a total market capitalization of HK$12.6 billion. Goldman Sachs published a report upgrading Kangji Healthcare's stock rating from “neutral” to “buy”, and the target price soared 80% from HK$7.6 to HK$13.7, reflecting the high visibility of minimally invasive surgery (MIS) recovery after the Lunar New Year, the gradual return to normal patient flow, and the impact of centralized drug procurement may be manageable in the short term. The bank mentioned that the group's valuation is relatively attractive. The annual price-earnings ratio is 17.5 times, and the earnings per share forecast for 2022 to 2024 is expected to reach 29%.